A gene deletion that up-regulates viral gene expression yields an attenuated RSV vaccine with improved antibody responses in children.
about
In Hot Pursuit of the First Vaccine Against Respiratory Syncytial VirusViral Infection in the Development and Progression of Pediatric Acute Respiratory Distress SyndromeEarly-life respiratory infections and asthma development: role in disease pathogenesis and potential targets for disease preventionDefining the vaccination window for respiratory syncytial virus (RSV) using age-seroprevalence data for children in Kilifi, Kenya.Age-Specific Profiles of Antibody Responses against Respiratory Syncytial Virus Infection.A live RSV vaccine with engineered thermostability is immunogenic in cotton rats despite high attenuationProgress toward a Respiratory Syncytial Virus VaccineVaccines against respiratory syncytial virus: The time has finally come.Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.Vaccination strategies against respiratory syncytial virus.Respiratory syncytial virus infection: an innate perspective.Immunological Features of Respiratory Syncytial Virus-Caused Pneumonia-Implications for Vaccine DesignFunctional motifs responsible for human metapneumovirus M2-2-mediated innate immune evasion.Respiratory syncytial virus vaccines: an update on those in the immediate pipeline.Strategies to develop vaccines of pediatric interest.Vaccine development for respiratory syncytial virus.Passive and active immunization against respiratory syncytial virus for the young and old.Attenuated Human Parainfluenza Virus Type 1 Expressing the Respiratory Syncytial Virus (RSV) Fusion (F) Glycoprotein from an Added Gene: Effects of Prefusion Stabilization and Packaging of RSV F.Structural basis for human respiratory syncytial virus NS1-mediated modulation of host responses.Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored-Vaccine Candidate.Mutating the CX3C Motif in the G Protein Should Make a Live Respiratory Syncytial Virus Vaccine Safer and More Effective.Influence of antigen conformation and mode of presentation on the antibody and protective responses against human respiratory syncytial virus: relevance for vaccine development.RSV vaccine: Beating the virus at its own game.The Outpatient Burden of Respiratory Syncytial Virus Infections in Older Children.Vaccines Against Respiratory Syncytial Virus: The Time Has Come.Detection of Nuclear Protein Profile Changes by Human Metapneumovirus M2-2 Protein Using Quantitative Differential Proteomics.ENHANCING THE THERMOSTABILITY AND IMMUNOGENICITY OF AN RSV LIVE-ATTENUATED VACCINE BY INCORPORATING UNIQUE RSV LINE19F PROTEIN RESIDUES.Vaccines for the Paramyxoviruses and Pneumoviruses: Successes, Candidates, and Hurdles.Better understanding of childhood asthma, towards primary prevention - are we there yet? Consideration of pertinent literature.Past, Present and Future Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children.Live Respiratory Syncytial Virus (RSV) Vaccine Candidate Containing Stabilized Temperature-Sensitivity Mutations Is Highly Attenuated in RSV-Seronegative Infants and Children.Live-Attenuated Respiratory Syncytial Virus Vaccine Candidate With Deletion of RNA Synthesis Regulatory Protein M2-2 is Highly Immunogenic in Children.Effect of genetic background and delivery route on the preclinical properties of a live attenuated RSV vaccine.An optimized methodology for whole genome sequencing of RNA respiratory viruses from nasopharyngeal aspirates.Human Metapneumovirus: Mechanisms and Molecular Targets Used by the Virus to Avoid the Immune System
P2860
Q26748856-AD2C2A27-AD01-49AA-80F2-2387602C7276Q28071857-824F042D-F55A-4881-89C0-11D3102B08BCQ28076551-7C78514E-3F1D-4A6D-BE4B-E46856BC4854Q33712986-75FFC5C0-C123-4407-BDD6-26E47F276A40Q33809443-AA1D9A14-2802-4E53-89CD-3D55B07C1FF4Q34547769-4DA5E15F-44D9-4A65-970C-E2F840E976F2Q36665660-429C0195-692A-4785-A643-12C15BA012F3Q37018347-170AF0FD-9268-47B8-9F9F-24232576ACF6Q37347267-0665A971-3B6C-4900-9521-45E107F10A11Q37469280-B1C8CF0B-82C8-4932-B6C9-1AE78937DA24Q37577700-C8BF37AB-105C-4662-BEB9-AAB0ED17C86AQ37729137-349A9485-8A9F-4494-886B-C37BE3C8CA7FQ38741126-5469BDB3-AFF0-441C-8CFD-CF68887D45B7Q38803541-30370C6E-A7CD-4502-BA9C-7B2D2EEDE9C5Q38819027-AB922F93-3777-45A4-B69E-CF6603061B73Q39318444-A1ED95BC-29DF-4B81-9148-72F14BBBA5A5Q39318498-8674CE2E-0F2E-4A01-A04D-E7A608679795Q40072947-4CC8D608-F798-4DB4-86C4-88318E4D4B89Q40139880-E9A2A74D-21A5-42C9-BCCC-D323E79C5281Q40187606-0E267A8D-BA4C-41EA-8ECF-972CDDDE7D4EQ40301155-13346582-2B3F-437C-B187-F4151FFEA8B2Q40812866-37D7EBC4-2626-45BE-A661-64386D6355D2Q41149828-5653A30D-D768-45E8-B8A0-4CD2B9C10C72Q45332698-708CA35E-C223-4F59-A3B4-34CB72722FFAQ45332913-9394A4A6-9E02-4790-9BA6-7E1E79DB2AE1Q47160156-56379313-38C6-44D0-A8B6-91613448E00AQ47269161-B72088F6-994A-40F3-82D5-A9104028142BQ47555408-04A459E2-155E-4063-8678-05C8AED4A12EQ48247029-B4F84D6C-99E6-4F26-8007-66B5DA819B23Q50262223-2CB62DFE-D73A-4D7D-8D38-05034EB38F79Q54095931-C2188960-3D3E-401F-8A03-6E7DDE7E0BB9Q54261413-34EDC84F-4B09-47C8-93C1-9558CF15EFDAQ55317724-34EF88C0-7F21-4147-A043-BBFC8285E5A0Q55502695-02142EDC-8299-4DFA-9B84-649F44EE5643Q58566613-BC72E1F4-17C4-42BA-BB21-AE0BB63C3D41
P2860
A gene deletion that up-regulates viral gene expression yields an attenuated RSV vaccine with improved antibody responses in children.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
A gene deletion that up-regula ...... ntibody responses in children.
@en
type
label
A gene deletion that up-regula ...... ntibody responses in children.
@en
prefLabel
A gene deletion that up-regula ...... ntibody responses in children.
@en
P2093
P2860
P1476
A gene deletion that up-regula ...... antibody responses in children
@en
P2093
Bhagvanji Thumar
Cindy Luongo
Janet A Englund
Karen M Loehr
Peter L Collins
Ursula J Buchholz
P2860
P304
P356
10.1126/SCITRANSLMED.AAC8463
P407
P577
2015-11-01T00:00:00Z